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surgery 42%). The questionnaire was sent out twelve
weeks after discharge and covered the period since. Reli-
ability was assessed by comparing the 12-week question-
naire with a cost diary which patients were asked to ﬁll
in prospectively during the ﬁrst 4 weeks after discharge.
RESULTS: The 3-month questionnaire showed a re-
sponse rate of 88%. Ninety two percent of respondents
found the questionnaire easy or very easy to ﬁll in. Rate
of completion was close to 100% for all items. Time for
completion took on average 27 minutes. Comparison
with the data collected by the prospective cost diary
showed modest to good correlation for the overlapping
period. Intraclass correlation coefﬁcients ranged from
0.57 (cost of daily drug intake) to 0.9 (hospital days).
CONCLUSIONS: The instrument showed good accep-
tance and feasibility as well as reasonable reliability when
compared to a detailed prospective cost diary. Therefore
the instrument appears to be an efﬁcient alternative for
patient oriented cost measurement. With respect to relia-
bility further suggestions for improvement of the instru-
ment were developed where indicated.
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OBJECTIVE: To perform a pharmacoepidemiologic
analysis on the utilization and cost of statins in secondary
care practice in non-experimental setting. METHODS:
The Ravenna Local Health Unit administrative database
(approximately 350,000 subjects) was used to perform 
a registry of Acute Myocardial Infarction (AMI) since
1996. The registry was made by the linkages among
patients’ baseline characteristics, hospital admissions and
drug prescriptions. A 6-month follow-up study included
all subjects discharged alive from the hospital after AMI
during the period 1996–2000. Patients with previous
AMI since 1991 and those not in the province’s databases
for the entire follow-up were excluded. Drug prescrip-
tions data were processed for statins (ATC Code C10A),
ACE-inhibitors (C09A even if associated with C09B),
beta-blockers (C07), other antihypertensives (C02, C03,
C08, C09C and C09D), as well as for aspirin (B01AC06),
antidiabetic drugs (A10A and A10B), cardiac drugs (C01)
and other antiaggregants (B01AA and B01AB,
B01AC05). Drug cost was evaluated at NHS purchase
prices. RESULTS: A total of 2265 subjects were enrolled
(446 in 1996, 440 in 1997, 443 in 1998, 443 in 1999,
and 493 in 2000). The percentage of patients prescribed
for statins increased each year (from 22.6% in 1996 to
43.8% in 2000) as well as the percentage of those pre-
scribed for aspirin (from 48.0% in 1996 to 80.5% in
2000) and beta-blockers (from 27.4% in 1996 to 41.0%
in 2000). Overall cost for statins accounted to €10,610
in 1996, €15,344 in 1997, €23,483 in 1998, €35,910 in
1999, and €45,103 in 2000. Average cost for patients pre-
scribed for statins ranged from €105.05 in 1996 to
€208.81 in 2000 and increased over each year. CON-
CLUSIONS: Evidence from secondary care practice in the
province of Ravenna highlights a trend for more frequent
use of statins, aspirin and beta-blockers after discharge
for AMI.
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OBJECTIVES: The Finnish Health For All 2000 target
set in the mid-1980s (at least 80% non-smoking) was not
realised. Actually, prevalence of smoking has remained
rather constant during the 1990s even after introduction
of over-the-counter nicotine replacement (NRT) options.
Our intent was to model cost-effectiveness of six methods
(willpower, physician advice, NRT [patch, gum, spray],
bupropion) to quit smoking as applied in Finnish health
care. METHODS: Data on efﬁcacy (% successfully quit
smoking during 12 months’ observation period) were
obtained from published meta-analyses and original arti-
cles. Cost data included only direct costs (physician visits,
medications, adverse events [occurrence 1% in each treat-
ment]). Costs were estimated using societal perspective (in
year 2000 Euros). Decision-tree based average cost-
effectiveness estimates (€/additional quitter) and incre-
mental cost-effectiveness ratios (ICER) were derived by
using Data 3.5 software. Two-way sensitivity analyses
were performed. RESULTS: Efﬁcacy of willpower (1%)
and physician advice (3%) were the lowest, followed by
NRT patch (13%) and NRT gum (18%) whereas higher
for NRT spray (24%) and bupropion (30%). Costs of
willpower were set to zero by deﬁnition. Cost per addi-
tional quitter of bupropion (€954) treatment was the
lowest, and NRT spray (€2397) the highest. Bupropion
dominated over NRT gum and spray. ICER of NRT patch
vs. physician advice was €1495 (€804 for bupropion)
whereas ICER of bupropion vs. NRT patch was €404.
Sensitivity analyses showed results were robust. CON-
CLUSIONS: Short-term decision-tree analysis suggests
that bupropion is a cost-effective option for physicians in
order to help motivated smokers to quit smoking in
Finnish health care settings.
PCV34
COST-EFFECTIVENESS OF PATHOGEN
INACTIVATION FOR PLATELET TRANSFUSIONS
IN DUTCH CARDIAC SURGERY
Postma MJ1, de Wolf JT2, van Hulst M1, Staginnus U3,
Smit Sibinga CT4
1Groningen University Institute for Drug
Exploration/university of Groningen Research Institute of
Pharmacy (GUIDE/GRIP), Groningen, Netherlands; 2University
Hospital Groningen, Groningen, Netherlands; 3Baxter, S.L,
Madrid, Spain; 4Sanquin, Amsterdam, Netherlands
